Silvia Taylor is the executive vice president, and chief communications officer for Novavax. Ms. Taylor has responsibility for investor relations; public relations; external and internal communications; corporate social responsibility and ESG (environmental, social, and governance) strategy; digital and social media; and meetings, events, and corporate merchandising for the company. She brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was vice president of global corporate affairs and communications at Autolus Therapeutics plc, where she led all financial, scientific, and corporate communications. Prior to Autolus, Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing, responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as at Pfizer, where she served in key brand and consumer marketing roles. Ms. Taylor earned a Master of Business Administration degree from Columbia University and a Bachelor of Arts degree in foreign affairs from the University of Virginia. In 2022, she was elected to the Page Society, a membership organization of chief communications officers of global Fortune-ranked corporations.